Basic Information
Ikervis
Regulatory Information
EMEA/H/C/002066
Authorised
March 19, 2015
10
February 27, 2023
Company Information
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Ikervis. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union and its conditions of use. It is not intended to provide practical advice on how to use Ikervis. For practical information about using Ikervis, patients should read the package leaflet or contact their doctor or pharmacist.